Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up

Max Kates, MD, discusses how early complete response rates exceeding 50% at 3 months with newer therapies are encouraging, though long-term follow-up remains critical for evaluating durability of response and establishing real-world effectiveness compared with clinical trial outcomes.

EP: 1.Overview of BCG-Unresponsive NMIBC

EP: 2.Challenges of BCG-Unresponsive NMIBC

EP: 3.Standard Treatment Options for BCG-Unresponsive NMIBC

EP: 4.Unresponsive NMIBC: Gene Therapies

EP: 5.Gene Therapy Considerations for BCG-Unresponsive NMIBC

EP: 6.Gene Therapy Data for BCG-Unresponsive NMIBC

EP: 7.BCG-Unresponsive NMIBC: Insights for Newer Treatment Modalities

EP: 8.Addressing Challenges in BCG-Unresponsive NMIBC: Overview and Unmet Needs

EP: 9.Current Treatment Options for BCG-Unresponsive NMIBC

EP: 10.The Impact of Targeted Gene Therapy and Nadofaragene Firadenovec on BCG-Unresponsive NMIBC

Now Viewing

EP: 11.Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up

1. Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
   1. How do these clinical trial outcomes compare to what you see in your clinical practice when treating patients with newer therapies?
2. Discuss the importance of long-term follow-up for patients receiving these newer treatments.
   1. What is your experience in terms of durability of response?

Related Videos